Abstract
Introduction: Indonesia is one of ten countries with the largest diabetic populations in the world. Giving soy supplements to people with diabetes can reduce blood glucose levels significantly. However, no studies have shown a reduction back to normal glucose levels. This study aimed to determine the increase of insulin levels and blood glucose suppression in glucose tolerance tests after supplementation of soy in patients with type 2 diabetes. Sequencing the gene of GLP-1 (37 amino acid). This experimental research was a randomized, treatment controlled; open clinical trial study conducted by comparing the control group treated with soybean supplement products containing 18g protein and placebo. Seventy-six treatment subjects with type 2 diabetes were recruited from Muhammadiyah Gamping Hospital and PERSADIA gymnastics group according to the inclusion and exclusion criteria and then grouped randomly in the supplement treatment and placebo groups. Blood sampling was drawn at 8 hours fasting, 2 hours after supplement administration and 2 hours after administration of 75g glucose for measuring blood insulin and glucose level. Blood insulin level 2 hours after supplement administration (mean±SEM) increased 5.3±0.8µIU/ml (n=37) while placebo decreased 0.9±0.4µIU/ml (n=39) which was statistically significantly different ( p< 0.05). Blood glucose levels increased in the glucose tolerance tests, while the supplement group was 130.0±11.5mg/dl (n=37) lower than the placebo 146.7±8.2mg/dl (n=39) ( p> 0.05). Gene sequencing shows a nucleotide variation of GLP-1 (37 amino acid) in Javanese T2DM Giving Soybean supplements containing 18g protein increased blood insulin levels and suppressed blood glucose levels in glucose tolerance tests.
Highlights
The International Diabetes Federation (2015) estimates that people with diabetes mellitus (DM) in the world reached 415 million in 2015 and will increase to 642 million by 2040
There are no significant differences were found between the placebo and the supplement groups in the term of variables which may affect blood glucose level and or insulin level such as age, sex, body weight and BMI, profile lipids, the length of diagnose of DM
Some of the subjects are used to administer oral hypoglycemic agent or insulin or combination of the two, but at the time of having supplementation was assumed that the effect of all types of anti-diabetic agent were neglected (Table I)
Summary
The International Diabetes Federation (2015) estimates that people with diabetes mellitus (DM) in the world reached 415 million in 2015 and will increase to 642 million by 2040. Ten countries with the largest population of DM sufferers in the world are India, China, America, Indonesia, Japan, Pakistan, Russia, Brazil, Italy and Bangladesh (Khardori, 2016). DM is a risk factor for cardiovascular disease. It may be controlled by treatment with anti-diabetic drugs and dietary restrictions (Balitbangkes, 2013). DM management is conducted by the efforts of non-pharmacologic and pharmacologic treatment administration. Non-pharmacological interventions involve applying healthy lifestyles and pharmacological interventions by administering drugs orally and/or injections (PERKENI, 2015). Encouragement of herbal medicine (jamu) research based on health services promoted by Indonesian government
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
